Related Experiment Video
Updated: Jun 18, 2026
High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
Published on: August 3, 2011
miRquad: first-in-class dPCR multiplex TaqMan™ Advanced clinical research assay for microRNA detection in head and
Matteo Allegretti1, David J Joun2, Giulia Urbani1
1Translational Oncology Research Unit, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Background:
Cancer resistance is one of the major challenges in oncology, often resulting in disease relapse and poor patient outcomes. Within the RNA family, microRNAs (miRNAs) regulate core biological processes and have been recognized also as critical contributors of tumor resistance and therapy failure. Being pivotal, they are increasingly exploited as biomarkers in various settings. Although in silico analyses facilitate miRNAs identification, PCR-based approaches remain essential to validate their expression. Currently, a plethora of well-established, single-target methods exist but multiplex detection from the same input have been only rarely explored.
Methods:
We present miRquad, the first-in-class digital PCR (dPCR) TaqMan™ multiplex clinical research assay for miRNA detection in head and neck (HNC) cancers. Based on a patented prognostic signature including miR-21-5p, miR-96-5p, miR-21-3p and miR-429, the assay would enable simultaneous miRNA analysis via qPCR and dPCR on multiple clinically relevant sample types.
Results:
We designed and optimized miRquad using both synthetic controls and retrospective patient-derived tissues, sera and saliva. A multicentre ring study was conducted to evaluate assay reliability across different platforms, demonstrating strong correlation with commercial singleplexes, broad applicability, reduced turnaround time (TAT) and cost-effectiveness. Finally, we provide evidence for its potential clinical application to predict disease outcome in HNC, testing miRquad on tumoral and peritumoral tissues, sera and saliva samples collected throughout patient follow up.
Conclusions:
The assay overcomes common challenges associated with multiple miRNAs detection, particularly in liquid biopsy samples (e.g., multiple pipetting issues, increased consumption of sample for multiple assessment, extended TAT for complete profiling) and provides robust and accurate detection, demonstrating potential for real-time patient monitoring and prognostication in HNC.
Insights
This study introduces miRquad, a novel multiplex assay for detecting microRNAs (miRNAs) in head and neck cancers. The assay enables simultaneous analysis of multiple miRNAs, improving efficiency and accuracy for patient monitoring and prognostication.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Cancer resistance poses a significant challenge in oncology, leading to disease relapse and poor patient outcomes.
- MicroRNAs (miRNAs) are key regulators of biological processes and are implicated in tumor resistance and therapeutic failure.
- While in silico methods aid miRNA identification, PCR-based approaches are crucial for expression validation, yet multiplex detection remains underexplored.
Purpose of the Study:
- To introduce miRquad, the first digital PCR (dPCR) TaqMan™ multiplex assay for miRNA detection in head and neck cancers (HNC).
- To enable simultaneous analysis of a patented prognostic miRNA signature (miR-21-5p, miR-96-5p, miR-21-3p, miR-429) using qPCR and dPCR.
- To evaluate the assay's performance on various clinically relevant sample types.
Main Methods:
- Development and optimization of the miRquad assay using synthetic controls and patient-derived tissues, sera, and saliva.
- A multicenter ring study to assess assay reliability across different platforms.
- Validation of miRquad's clinical utility by testing on tumoral and peritumoral tissues, sera, and saliva samples from HNC patients throughout their follow-up.
Main Results:
- The miRquad assay demonstrated strong correlation with commercial singleplex assays, broad applicability, and reduced turnaround time (TAT) and cost-effectiveness.
- Optimization was achieved using both synthetic controls and retrospective patient samples.
- The assay showed potential for predicting disease outcomes in HNC patients.
Conclusions:
- miRquad effectively addresses challenges in multiplex miRNA detection, especially in liquid biopsies, by minimizing issues like multiple pipetting and sample consumption.
- The assay provides robust and accurate miRNA detection, offering potential for real-time patient monitoring and prognostication in HNC.
- This multiplex approach enhances efficiency and reduces TAT for comprehensive miRNA profiling.
